Hone Health review

Hone is a different medication decision

Hone Health should not be treated as another weekly semaglutide or tirzepatide seller. Its women’s weight-loss and treatment pages list compounded liraglutide, a daily injection, as the GLP-1 option. Semaglutide and tirzepatide are not listed in this treatment menu. That distinction changes the comparison before price enters it: a person seeking a particular weekly medication needs to know whether Hone’s actual treatment menu suits her clinician’s recommendation.

The service places weight management within hormone and longevity care, alongside concerns such as perimenopause, energy and sleep. Its menu also includes medications such as naltrexone, bupropion, topiramate and phentermine. Those are separate prescription choices, not interchangeable substitutes selected by a price table. A wider menu can support a broader conversation, but the public catalog does not prove that any one option is appropriate for an individual reader.

The Premium membership belongs in the total

Liraglutide is listed from $160 a month plus membership and labeled a Premium-tier treatment. The Premium membership is $155 a month, making the published recurring combination about $315 a month before any additional charges that may apply. Comparing $160 with another provider’s complete treatment price would leave out almost half of Hone’s stated recurring cost.

The initial biomarker panel is listed at $65, with a physician video consultation included in the testing offer. Hone describes more than 50 blood markers and testing through a partner location or a home draw where available. Its lower Basic membership does not establish access to every treatment: the tier table distinguishes Basic-labeled products from the Premium catalog. Ask which tier your proposed prescription requires rather than assuming that the cheapest membership unlocks the medication you came to investigate.

A testing-led process requires some patience

Hone describes a sequence of testing, physician review and medication delivery, rather than immediate prescribing from a shopping page. Its published timeline includes a physician consultation after testing and medication arriving later. These are advertised process milestones, not a guaranteed delivery date for a specific patient. Someone changing treatment, traveling or approaching the end of an existing supply should discuss continuity rather than building a schedule around the fastest displayed estimate.

Premium membership also describes testing every three months. That may appeal to someone who wants an ongoing laboratory component, especially when weight is only one part of the consultation. It also creates a practical commitment to obtaining samples and reviewing results. The relevant question is what the clinician will do with the information, how follow-up is arranged and which costs remain separate, rather than whether a large biomarker count is inherently better.

Women’s positioning has a specific, limited basis

Hone has a women’s weight-loss pathway and perimenopause-oriented positioning. Its liraglutide page explicitly warns against use during pregnancy or breastfeeding. These disclosures are useful subjects for the physician visit; they do not establish suitability for a postpartum or nursing patient. Ask about the clinician’s experience with the particular maternal or hormonal concern you want help managing.

Clinical care is attributed to Broad Health, described as an independent physician-owned group. Hone does not accept insurance, and its terms warn that services may not be available in every state without publishing a complete state list. Membership is described as month to month and cancelable, but fees already paid are not refundable. Hone therefore fits most naturally when someone wants its testing-led care model and its actual medication options. If the goal is specifically a weekly semaglutide or tirzepatide prescription, compare that requirement directly with other providers before paying for the initial panel.